THOMAS BURNS
CHAIRMAN/CEO
GLAUKOS
WHY: Has led ophthalmic company since 2002, helping company develop world’s smallest medical device, the iStent, which is inserted into an eye to help combat glaucoma.
IN THE NEWS: Shares have doubled in past year to $7B market cap.
NOTABLE: Analysts expect sales to climb 19% to $374M this year and then accelerate 24% to $464M in 2025.
QUOTABLE: “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
